Silexon Overview
- Year Founded
-
2018
- Status
-
Private
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$15.4M
- Investors
-
8
Silexon General Information
Description
Developer of AI-empowered drug discovery technology for pharmaceutical companies. The company specializes in AI technologies including drug repositioning platforms, macro-molecular design models, and AI virtual molecule screening to assist the generic drug discovery process, providing pharmaceutical researchers with technical and AI-based data analysis support.
Contact Information
Website
www.silexon.techCorporate Office
- Room 317-321, 3/F, Building F7
- No.9, Weidi Road, University City, Xianlin street, Qixia District
- Nanjing, Jiangsu
- China
Corporate Office
- Room 317-321, 3/F, Building F7
- No.9, Weidi Road, University City, Xianlin street, Qixia District
- Nanjing, Jiangsu
- China
Silexon Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 25-Jul-2021 | $15.4M | Completed | Generating Revenue | ||
| 1. Early Stage VC | 23-Nov-2019 | Completed | Generating Revenue |
Silexon Patents
Silexon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025000265-A1 | Heterocyclic compounds usefull as sos1 inhibitor | Inactive | 28-Jun-2023 | ||
| WO-2023138612-A1 | Heterocyclic compounds useful as hpk1 inhibitors | Inactive | 19-Jan-2022 | ||
| WO-2023125737-A1 | Heterocyclic compounds and use thereof | Inactive | 29-Dec-2021 | ||
| WO-2023284881-A1 | Heterocyclic compounds useful as kras g12d inhibitors | Inactive | 16-Jul-2021 | ||
| WO-2022262838-A1 | Deuterated compounds useful as kras g12d inhibitors | Inactive | 18-Jun-2021 | C07D519/00 |
Silexon Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eight Roads | Corporate Venture Capital | Minority | ||
| F-Prime | Venture Capital | Minority | ||
| HSG (Hong Kong) | Venture Capital | Minority | ||
| Quan Capital | Venture Capital | Minority | ||
| Ascendin Fund | Corporate Venture Capital | Minority |
Silexon FAQs
-
When was Silexon founded?
Silexon was founded in 2018.
-
Where is Silexon headquartered?
Silexon is headquartered in Nanjing, China.
-
What industry is Silexon in?
Silexon’s primary industry is Discovery Tools (Healthcare).
-
Is Silexon a private or public company?
Silexon is a Private company.
-
What is Silexon’s current revenue?
The current revenue for Silexon is .
-
How much funding has Silexon raised over time?
Silexon has raised $15.4M.
-
Who are Silexon’s investors?
Eight Roads, F-Prime, HSG (Hong Kong), Quan Capital, and Ascendin Fund are 5 of 8 investors who have invested in Silexon.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process